Case Study – Oncology Drug Market Strategy

Case Study

Oncology Drug Market Strategy

Research Objective

The client, a biotechnology company, wanted a go-to-market diagnostic test strategy for novel oncology drug with a focus on next-generation sequencing NGS vs. IHC.

Antibodies and cancer cell Cancer Oncology Drug

Targeted Countries

  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • United States

Sample Size

8 + 250


Qualitative + Quantitative

Targeted Designations

– Medical Lab Scientist

– Consultant Pathologist

– Laboratory Manager

– Laboratory Director


Patient flow and diagnostic test processes were mapped across multiple clinic business models.

  • The drivers and hurdles to NGS adoption were identified.
  • NGS, liquid biopsy, and IHC are all expected to be used in the future.
  • Alternatives and recommendations for a companion diagnostic strategy.